Table 2.
Anti-PD-L1 antibody alone or in combination with other treatments in RCC patients
| Agents | Phase | Participants | Dose | Outcome | Refs. |
|---|---|---|---|---|---|
| Atezolizumab Bevacizumab | 2 | 305 |
1200 mg 15 mg/kg |
Improved PFS, which had no association with tumor mutation and neoantigen burden | [179] |
| Atezolizumab Bevacizumab | 3 | 915 |
1200 mg 15 mg/kg |
Improved PFS versus sunitinib (11·2 months versus 7.7 months) with a favorable safety profile | [175] |
|
Atezolizumab Cabozantinib |
1b | 102 |
1200 mg 40–60 mg |
Prolonged PFS to19.5 months | [226] |
| Atezolizumab Bevacizumab | 2 | 59 |
1200 mg 15 mg/kg |
Improved PFS (8.7 moths) with detection of TRAEs in 83% of patients | [227] |
| Atezolizumab Interferon-α | 1b | 158 |
1200 mg 180 μg |
Significant ORR (20.0%) | [184] |
| Atezolizumab | 1 | 17 | 0.01–20 mg/kg | Improved OS (28.9 months) and PFS (5.6 months) | [177] |
|
Atezolizumab Navoximod |
1 | 157 | 50–1000 mg | Acceptable safety, tolerability, and pharmacokinetics | [228] |
|
Avelumab Axitinib |
3 | 886 |
10 mg/kg 5 mg |
Prolonged PFS and OS versus sunitinib which was in association with below-median NLR | [199, 229] |
|
Atezolizumab A2AR antagonist |
1 | 68 |
840 mg 50–100 mg |
A durable clinical benefit associated with increased CTLs infiltration into the tumor | [230] |
Note: Programmed cell death ligand 1 (PD-L1), Renal cell carcinoma (RCC), Overall survival (OS), Objective response rate (ORR), Progression-free survival (PFS), Adenosine A2A receptor (A2AR), Treatment-related adverse events (TRAEs), Neutrophil–lymphocyte ratio (NLR), Cytotoxic T cells (CTLs)